Oxidative damage and cone cell death in RP
Oxidative damage and cone cell death in RP
批准号:
7384414
负责人:
Peter A Campochiaro
金额:
$50.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-09-30 至 2012-02-29
关键词:
AddressAgeAge related macular degenerationAmericanAnimal ModelAntioxidantsBlindnessBrain-Derived Neurotrophic FactorCell DeathCessation of lifeDataDevelopmentDiseaseEnzymesFamily suidaeFutureGene TransferGoalsHyperoxiaInheritedInjection of therapeutic agentKnockout MiceMediatingModelingMusMutateParaquatPathogenesisPatientsPhotoreceptorsPlayProcessProductionProtein IsoformsProtein OverexpressionPublic HealthRateRetinal ConeRetinal DegenerationRetinitis PigmentosaRhodopsinRoleSOD2 geneSuperoxide DismutaseSus scrofaSystemTestingTherapeuticTransgenesTransgenic OrganismsVertebrate PhotoreceptorsWorkadeno-associated viral vectorgene therapygene therapy clinical trialmouse modelneurotrophic factornovelresearch studyretinal rodssuperoxide dismutase 1therapeutic targetvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Several lines of evidence suggest that oxidative damage plays a role in the pathogenesis of age-related macular degeneration (AMD). We hypothesize that oxidative damage also plays an important role in cone cell death in retinitis pigmentosa (RP). If this is true, increased expression of antioxidant enzymes in photoreceptors may be a good therapeutic strategy in both disease processes. In this proposal, we plan to explore the role of the 3 isoforms of superoxide dismutase (SOD) in the oxidative defense system of photoreceptors. To assess the role of endogenous SODs, the effect of deficiency of SOD1 or 3 on photoreceptor survival will be tested in two models of oxidative damage, hyperoxia- and paraquat-induced retinal degeneration. The same two models, along with transgenic and self-complementary adeno- associated viral vector (scAAV)-mediated gene transfer approaches, will be used to test the hypothesis that increased expression of SOD 1, 2, or 3 protects photoreceptors from oxidative damage. The hypothesis that oxidative damage contributes to cone cell death in RP will be tested by determining if increased expression of SOD 1, 2, or 3 reduces cone cell death in two mouse models of RP. The data from all of these experiments in mice will help us to select the appropriate transgene(s) for definitive experiments in a transgenic pig model of RP. In those experiments scAAV-mediated gene transfer of an SOD or combination of SODs will be tested against null vector to determine if increased production of SOD(s) reduces cone cell death. The effects of SOD(s) alone will also be compared to co-expression of SOD(s) with brain-derived neurotrophic factor (BDNF) to determine if the co-expression approach provides additive benefit for cone survival. The major goal of this work is to develop a new gene therapy to promote cone survival in patients with RP. If benefit is demonstrated in preserving cones in patients with RP, a similar strategy could be tested in the future to see if it protects both rods and cones in patients with AMD.
This study addresses a major public health problem in the US, inherited retinal degenerations, for which there is currently no effective treatment. In addition, the results may also be applicable to AMD, the most prevalent cause of severe vision loss in Americans over the age of 60.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
-
批准号:10333382
-
项目类别:
-
资助金额:$34.24万
-
财政年份:2022
-
负责人:Peter A Campochiaro
-
依托单位:
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa
-
批准号:10593947
-
项目类别:
-
资助金额:$42.8万
-
财政年份:2022
-
负责人:Peter A Campochiaro
-
依托单位:
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists
-
批准号:10557124
-
项目类别:
-
资助金额:$59.89万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases
-
批准号:10549354
-
项目类别:
-
资助金额:$40.94万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseases
-
批准号:10326840
-
项目类别:
-
资助金额:$39.71万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
Suprachoroidal nonviral gene transfer of engineered VEGF antagonists
-
批准号:10093050
-
项目类别:
-
资助金额:$58.1万
-
财政年份:2020
-
负责人:Peter A Campochiaro
-
依托单位:
Integrin-binding Peptide for Ocular Neovascularization and Macular Edema: Molecular Mechanism of Action
-
批准号:10361561
-
项目类别:
-
资助金额:$39.71万
-
财政年份:2019
-
负责人:Peter A Campochiaro
-
依托单位:
Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases
-
批准号:9317491
-
项目类别:
-
资助金额:$20.44万
-
财政年份:2016
-
负责人:Peter A Campochiaro
-
依托单位:
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye
-
批准号:8964295
-
项目类别:
-
资助金额:$42.25万
-
财政年份:2015
-
负责人:Peter A Campochiaro
-
依托单位:
Biomaterial Inhibitor of HIF-1 for Prolonged Anti-Angiogenesis in Eye
-
批准号:9256464
-
项目类别:
-
资助金额:$42.25万
-
财政年份:2015
-
负责人:Peter A Campochiaro
-
依托单位:
Novel Biodegradable Injectable Rod for Improved AMD Therapy
-
批准号:8647445
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:Peter A Campochiaro
-
依托单位:
RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
-
批准号:6342681
-
项目类别:
-
资助金额:$27.44万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
RETINAL NEOVASCULARIZATION IN DIABETIC RETINOPATHY
-
批准号:2761264
-
项目类别:
-
资助金额:$27.38万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6622273
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6721137
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Targeting survival factors for ocular neovascularization
-
批准号:7211882
-
项目类别:
-
资助金额:$40.97万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6840788
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Targeting survival factors for ocular neovascularization
-
批准号:7587922
-
项目类别:
-
资助金额:$39.4万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
New Treatments of Ocular Neovascularization and Macular Edema
-
批准号:8441484
-
项目类别:
-
资助金额:$38.48万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
Molecular Signals Involved in Ocular Neovascularization
-
批准号:6444529
-
项目类别:
-
资助金额:$28.61万
-
财政年份:1999
-
负责人:Peter A Campochiaro
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: